Loading...

Kathleen Rodgers, PhD

TitleAssociate Professor
InstitutionUniversity of Southern California
DepartmentClinical Pharmacy and Pharmaceutical Econ. and Policy
AddressPSC 530
Health Sciences Campus
Los Angeles CA 90089-9121
Phone+1 323 442 2574
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Kathleen E. Rodgers, PhD, is an Associate Professor in the Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy in the School of Pharmacy at the University of Southern California. Throughout her career, Dr. Rodgers has conducted research into a broad array of topics including gynecological cancers, medical device safety, drug effectiveness and toxicology.

    Since joining USC in 1986, she has been interested in applied research. Early in her career, she continued her doctoral research in the immunotoxicology of organophosphate pesticides. Her research interests also included the development of an immunoassay for gynecological cancers and an understanding of the process of peritoneal healing and the formation of intraperitoneal adhesions. After identification of key processes in these healing events, one focus became the identification of therapeutic interventions by which adhesions can be prevented. Further, she discovered that molecules generated by the renin angiotensin system have potential therapeutic benefit.

    The current focus of her basic science research is the cellular and molecular mechanisms by which angiotensin peptides accelerated tissue regeneration. Studies have shown that there is a primary effect on adult stem cell proliferation and homing. Further, there is an expertise within her laboratory in development of animal models relevant to surgical injuries and to provide and conduct developmental plans to optimized product delivery and efficacy. As her focus has been to provide translational assistance from the bench to the patient, she has spent time consulting for companies interested in developing products within her areas of expertise. Further, she has developed recommended panels of safety studies to allow conduct of clinical trials under FDA and EU supervision. Most recently, her basic research has developed to the point that three clinical trials involving the molecules developed through her research will soon be initiated.

    She is the holder of 42 US Patents and corresponding international filings that protect the commercial products that might be developed. The University is the holder of these patents and has recently licensed these patents to small biotechnology companies. She provided pre-clinical support, the oversight of the toxicological studies to enable the regulatory filings to allow clinical trials and input on the development of clinical protocols.

    National and international organizations that she has worked with include: (1) World Health Organization on three committees ((a) Immunotoxicology of Pesticides; (b) Women’s Health and Implantable Contraceptive; (c) Autoimmunity and Environmental Influences) ; (2) National Research Council (Commision of Life Sciences, Committee on Toxicology Board on Environmental Studies and Toxicology; Subcommittee on Biological Markers of Immunotoxicology); (3) Institute of Medicine (Committee to Review Health Effects in Vietnam Veterans of Exposure to Herbicides).


    Collapse Research 
    Collapse Research Activities and Funding
    NorLeu3-A(1-7): Enhanced Recovery of Radiation Burns
    NIH/NIAID RC1AI080976Sep 2, 2008 - Feb 29, 2012
    Role: Principal Investigator
    A(1-7)-Mediated Mitigation of Radiation Induced Thrombocytopenia
    NIH/NIAID RC1AI080223Jul 4, 2008 - Dec 31, 2011
    Role: Principal Investigator
    Angiotensin(1-7): A Target in Diabetic Cardiac Ischemia
    NIH/NHLBI R01HL082722Apr 8, 2008 - Mar 31, 2014
    Role: Principal Investigator
    Angiotensin Analogs to Treat Wound Healing
    NIH/NIDDK R44DK076425May 1, 2007 - Apr 30, 2011
    Role: Principal Investigator
    Angiotensin Analogs to Treat Wound Healing
    NIH/NIAMS R44AR047481Sep 1, 2004 - Aug 31, 2006
    Role: Principal Investigator
    ANGIOTENSIN ANALOGS TO TREAT WOUND HEALING
    NIH/NIAMS R43AR047481Sep 30, 2001 - Mar 31, 2002
    Role: Principal Investigator
    MOLECULAR MECHANISMS OF ORGANOPHOSPHATE IMMUNOTOXICITY
    NIH/NIEHS R01ES004337Sep 1, 1986 - Jun 30, 1998
    Role: Principal Investigator
    MOLECULAR MECHANISMS OF ORGANOPHOSPHATE IMMUNOTOXICITY
    NIH/NIEHS R29ES004337Sep 1, 1986 - Jun 30, 1993
    Role: Principal Investigator
    MOLECULAR MECHANISMS OF ORGANOPHOSPHATE IMMUNOTOXICITY
    NIH/NIEHS R23ES004337Sep 1, 1986 - Aug 31, 1989
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Nation DA, Tan A, Dutt S, McIntosh EC, Yew B, Ho JK, Blanken AE, Jang JY, Rodgers K, Gaubert A. Circulating Progenitor Cells Correlate with Memory, Posterior Cortical Thickness, and Hippocampal Perfusion. J Alzheimers Dis. 2018; 61(1):91-101. PMID: 29103037.
      View in: PubMed
    2. Rodgers K, Jadhav SS. The application of mesenchymal stem cells to treat thermal and radiation burns. Adv Drug Deliv Rev. 2018 Jan 01; 123:75-81. PMID: 29031640.
      View in: PubMed
    3. Soto M, Bang SI, McCombs J, Rodgers K. Renin Angiotensin system-modifying therapies are associated with improved pulmonary health. Clin Diabetes Endocrinol. 2017; 3:6. PMID: 28702260.
      View in: PubMed
    4. Rodgers K, Tan A, Kim L, Espinoza T, Meeks C, Johnston W, Maulhardt H, Donald M, Hill C, diZerega GS. Development of a guinea pig cutaneous radiation injury model using low penetrating X-rays. Int J Radiat Biol. 2016 08; 92(8):434-43. PMID: 27258737.
      View in: PubMed
    5. Abdallah WF, Louie SG, Zhang Y, Rodgers K, Sivok E, S diZerega G, Humayun MS. NorLeu3A(1-7) Accelerates Clear Corneal Full Thickness Wound Healing. Invest Ophthalmol Vis Sci. 2016 Apr 01; 57(4):2187-94. PMID: 27116546.
      View in: PubMed
    6. Papinska AM, Soto M, Meeks CJ, Rodgers K. Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol Res. 2016 05; 107:372-380. PMID: 26956523; PMCID: PMC4867244 [Available on 05/01/17].
    7. Aboye T, Meeks CJ, Majumder S, Shekhtman A, Rodgers K, Camarero JA. Design of a MCoTI-Based Cyclotide with Angiotensin (1-7)-Like Activity. Molecules. 2016 Jan 26; 21(2):152. PMID: 26821010; PMCID: PMC4795166.
    8. Rodgers K, Papinska A, Mordwinkin N. Regulatory aspects of small molecule drugs for heart regeneration. Adv Drug Deliv Rev. 2016 Jan 15; 96:245-52. PMID: 26150343.
      View in: PubMed
    9. Jadhav SS, Meeks CJ, Mordwinkin NM, Espinoza TB, Louie SG, diZerega GS, Rodgers K. Effect of combined radiation injury on cell death and inflammation in skin. Apoptosis. 2015 Jul; 20(7):892-906. PMID: 25772546.
      View in: PubMed
    10. Asatryan L, Khoja S, Rodgers K, Alkana RL, Tsukamoto H, Davies DL. Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. J Neuroimmunol. 2015 Aug 15; 285:169-79. PMID: 26198936; PMCID: PMC4512299.
    11. Irwin RW, Solinsky CM, Loya CM, Salituro FG, Rodgers K, Bauer G, Rogawski MA, Brinton RD. Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease. PLoS One. 2015; 10(6):e0128313. PMID: 26039057.
      View in: PubMed
    12. Rodgers K, Bolton LL, Verco S, diZerega GS. NorLeu3-Angiotensin (1-7) [DSC127] as a Therapy for the Healing of Diabetic Foot Ulcers. Adv Wound Care (New Rochelle). 2015 Jun 01; 4(6):339-345. PMID: 26029484.
      View in: PubMed
    13. Yardley MM, Huynh N, Rodgers K, Alkana RL, Davies DL. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol. 2015 Sep; 49(6):553-9. PMID: 26095588; PMCID: PMC4554813.
    14. Rodgers K, Peterson KJ, Maulhardt HA, diZerega GS. Angiotensin 1 - 7 stimulation of platelet recovery. Expert Opin Investig Drugs. 2014 Apr; 23(4):551-9. PMID: 24555825.
      View in: PubMed
    15. Rodgers K, Dizerega GS. Contribution of the Local RAS to Hematopoietic Function: A Novel Therapeutic Target. Front Endocrinol (Lausanne). 2013 Oct 23; 4:157. PMID: 24167502; PMCID: PMC3805949.
    16. Rodgers K, Espinoza TB, Roda N, Meeks CJ, diZerega GS. Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1235-45. PMID: 24091850.
      View in: PubMed
    17. Shah M, Edman MC, Janga SR, Shi P, Dhandhukia J, Liu S, Louie SG, Rodgers K, Mackay JA, Hamm-Alvarez SF. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome. J Control Release. 2013 Nov 10; 171(3):269-79. PMID: 23892265; PMCID: PMC3796004.
    18. Hajjar I, Rodgers K. Do angiotensin receptor blockers prevent Alzheimer's disease? Curr Opin Cardiol. 2013 Jul; 28(4):417-25. PMID: 23703253.
      View in: PubMed
    19. Pham H, Schwartz BM, Delmore JE, Reed E, Cruickshank S, Drummond L, Rodgers K, Peterson KJ, diZerega GS. Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2013 Apr; 71(4):965-72. PMID: 23370663.
      View in: PubMed
    20. Jadhav SS, Sharma N, Meeks CJ, Mordwinkin NM, Espinoza TB, Roda NR, DiZerega GS, Hill CK, Louie SG, Rodgers K. Effects of combined radiation and burn injury on the renin-angiotensin system. Wound Repair Regen. 2013 Jan-Feb; 21(1):131-40. PMID: 23231670; PMCID: PMC3540151.
    21. Mordwinkin NM, Ouzounian JG, Yedigarova L, Montoro MN, Louie SG, Rodgers K. Alteration of endothelial function markers in women with gestational diabetes and their fetuses. J Matern Fetal Neonatal Med. 2013 Mar; 26(5):507-12. PMID: 23046386; PMCID: PMC3622728.
    22. Balingit PP, Armstrong DG, Reyzelman AM, Bolton L, Verco SJ, Rodgers K, Nigh KA, diZerega GS. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial. Wound Repair Regen. 2012 Jul-Aug; 20(4):482-90. PMID: 22672145.
      View in: PubMed
    23. Rodgers K, Espinoza T, Roda N, Meeks CJ, Hill C, Louie SG, Dizerega GS. Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation. Int J Radiat Biol. 2012 Jun; 88(6):466-76. PMID: 22433112.
      View in: PubMed
    24. Rodgers K, Verco S, Bolton L, Dizerega G. Accelerated healing of diabetic wounds by NorLeu(3)-angiotensin (1-7). Expert Opin Investig Drugs. 2011 Nov; 20(11):1575-81. PMID: 21973177; PMCID: PMC3237292.
    25. Mordwinkin NM, Russell JR, Burke AS, Dizerega GS, Louie SG, Rodgers K. Toxicological and toxicokinetic analysis of angiotensin (1-7) in two species. J Pharm Sci. 2012 Jan; 101(1):373-80. PMID: 21858825; PMCID: PMC3619381.
    26. Rodgers K, Burleson FG, Burleson GR, Wolfsegger MJ, Lewis KM, Redl H. Two-component polyethylene glycol surgical sealant influence on intraperitoneal infection in a refined rodent model. Am J Obstet Gynecol. 2010 Nov; 203(5):494.e1-6. PMID: 20810099.
      View in: PubMed
    27. Cui H, Gensini M, Kataria R, Twaddle T, Zhang J, Wadsworth S, Petrilli J, Rodgers K, diZerega G, Cooper K. Reducing post-surgical adhesions utilizing a drug-enhanced device: sodium carboxymethylcellulose aqueous gel/poly(p-dioxanone) and Tranilast. Biomed Mater. 2009 Feb; 4(1):015001. PMID: 18981543.
      View in: PubMed
    28. Petrilli J, Wadsworth S, Cooper K, Rodgers K, Siekierka J, diZerega GS. Tranilast: a pharmaceutical candidate for reduction of adhesions using a novel approach. Semin Reprod Med. 2008 Jul; 26(4):341-8. PMID: 18756411.
      View in: PubMed
    29. Hwang J, Rodgers K, Oliver JC, Schluep T. Alpha-methylprednisolone conjugated cyclodextrin polymer-based nanoparticles for rheumatoid arthritis therapy. Int J Nanomedicine. 2008; 3(3):359-71. PMID: 18990945; PMCID: PMC2626937.
    30. Cooper K, Young J, Wadsworth S, Cui H, diZerega GS, Rodgers K. Reduction of post-surgical adhesion formation with tranilast. J Surg Res. 2007 Aug; 141(2):153-61. PMID: 17560610.
      View in: PubMed
    31. diZerega GS, Cortese S, Rodgers K, Block KM, Falcone SJ, Juarez TG, Berg R. A modern biomaterial for adhesion prevention. J Biomed Mater Res B Appl Biomater. 2007 Apr; 81(1):239-50. PMID: 16969823.
      View in: PubMed
    32. Rodgers K, Ellefson DD, Espinoza T, Hsu YH, diZerega GS, Mehrian-Shai R. Expression of intracellular filament, collagen, and collagenase genes in diabetic and normal skin after injury. Wound Repair Regen. 2006 May-Jun; 14(3):298-305. PMID: 16808808.
      View in: PubMed
    33. Rodgers K, Oliver J, diZerega GS. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 2006 May; 57(5):559-68. PMID: 16096787.
      View in: PubMed
    34. Rodgers K. Technology evaluation: Chrysalin (Orthologic). Curr Opin Mol Ther. 2005 Jun; 7(3):264-72. PMID: 15977425.
      View in: PubMed
    35. Rodgers K, Ellefson DD, Espinoza T, Roda N, Maldonado S, Dizerega GS. Effect of NorLeu3-A(1-7) on scar formation over time after full-thickness incision injury in the rat. Wound Repair Regen. 2005 May-Jun; 13(3):309-17. PMID: 15953051.
      View in: PubMed
    36. Rodgers K, Roda N, Felix JE, Espinoza T, Maldonado S, diZerega G. Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice. Exp Dermatol. 2003 Dec; 12(6):784-90. PMID: 14714558.
      View in: PubMed
    37. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S, Rodgers K. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol. 2004 Jan; 53(1):15-24. PMID: 14569417.
      View in: PubMed
    38. Rodgers K, Robertson JT, Espinoza T, Oppelt W, Cortese S, diZerega GS, Berg RA. Reduction of epidural fibrosis in lumbar surgery with Oxiplex adhesion barriers of carboxymethylcellulose and polyethylene oxide. Spine J. 2003 Jul-Aug; 3(4):277-83; discussion 284. PMID: 14589186.
      View in: PubMed
    39. Rodgers K, Espinoza T, Felix J, Roda N, Maldonado S, diZerega G. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7). Plast Reconstr Surg. 2003 Mar; 111(3):1195-206. PMID: 12621191.
      View in: PubMed
    40. Conroy SE, Baines L, Rodgers K, Deviren F, Verco SJ. Prevention of chemotherapy-induced intraperitoneal adhesion formation in rats by icodextrin at a range of concentrations. Gynecol Oncol. 2003 Mar; 88(3):304-8. PMID: 12648579.
      View in: PubMed
    41. Rodgers K, Xiong S, DiZerega GS. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemother Pharmacol. 2003 Feb; 51(2):97-106. PMID: 12647010.
      View in: PubMed
    42. Rodgers K, Xiong S, diZerega GS. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemother Pharmacol. 2002 May; 49(5):403-11. PMID: 11976835.
      View in: PubMed